- Home
- ENLT vs AKRO Comparison
ENLT vs AKRO Comparison
Compare ENLT & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENLT
- AKRO
- Stock Information
- Founded
- ENLT 2008
- AKRO 2017
- Country
- ENLT Israel
- AKRO United States
- Employees
- ENLT N/A
- AKRO N/A
- Industry
- ENLT
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- ENLT
- AKRO Health Care
- Exchange
- ENLT Nasdaq
- AKRO Nasdaq
- Market Cap
- ENLT 2.0B
- AKRO 3.9B
- IPO Year
- ENLT 2023
- AKRO 2019
- Fundamental
- Price
- ENLT $23.74
- AKRO $51.41
- Analyst Decision
- ENLT Buy
- AKRO Strong Buy
- Analyst Count
- ENLT 3
- AKRO 6
- Target Price
- ENLT $19.67
- AKRO $82.50
- AVG Volume (30 Days)
- ENLT 43.3K
- AKRO 1.8M
- Earning Date
- ENLT 08-06-2025
- AKRO 08-08-2025
- Dividend Yield
- ENLT N/A
- AKRO N/A
- EPS Growth
- ENLT 90.47
- AKRO N/A
- EPS
- ENLT 0.98
- AKRO N/A
- Revenue
- ENLT $397,296,000.00
- AKRO N/A
- Revenue This Year
- ENLT $355.90
- AKRO N/A
- Revenue Next Year
- ENLT $42.83
- AKRO N/A
- P/E Ratio
- ENLT $24.26
- AKRO N/A
- Revenue Growth
- ENLT 44.42
- AKRO N/A
- 52 Week Low
- ENLT $14.01
- AKRO $21.02
- 52 Week High
- ENLT $23.83
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- ENLT 73.22
- AKRO 47.91
- Support Level
- ENLT $22.61
- AKRO $53.05
- Resistance Level
- ENLT $23.72
- AKRO $57.35
- Average True Range (ATR)
- ENLT 0.47
- AKRO 2.45
- MACD
- ENLT 0.27
- AKRO -0.64
- Stochastic Oscillator
- ENLT 99.46
- AKRO 4.65
About ENLT Enlight Renewable Energy Ltd.
Enlight Renewable Energy Ltd develops, finances, constructs, owns, and operates utility-scale renewable energy projects. The company's operating segments are the MENA segment, Europe segment, U.S.A segment, and Others. It generates the majority of its revenue from the Europe segment, which produces its revenue from the sale of the electricity that is produced through wind energy and solar energy in Europe.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.